ANXA2 and precursor B-cell acute lymphoblastic leukemia: Although patient numbers are too small to draw definitive conclusions, immunohistochemistry of bone sections of patients with B-ALL, AML or multiple myeloma (the latter acting as control) may tentatively support our murine data with regards to expression of ANXA2 (Fig. 8D; Supplementary Fig. 21A), plasmin/-ogen (Fig. 8D; Supplementary Fig. 21B), fibronectin and IGF1 (Fig. 8D; Supplementary Fig. 21C, D) in some B-ALL samples compared to multiple myeloma.